MICROENCAPSULATED ANTIBIOTICS AND VITAMINS FOR LARVAL SHRIMP

Period of Performance: 01/01/1991 - 12/31/1991

$36.7K

Phase 1 SBIR

Recipient Firm

Rangen, Inc.
P.O. Box 706, 115 13th Ave. S.
Buhl, ID 83316
Principal Investigator

Abstract

TREATMENT OF DISEASED FINFISH AND SHRIMP LARVAE IS LIMITED TO CONTACT EXPOSURE WITH CHEMICALS ADMINISTERED IN THE WATER. HOWEVER, LARVAE REQUIRE INGESTION OF APPROPRIATE ANTIBIOTICS FOR FAST, EFFECTIVE RECOVERY FROM SYSTEMIC BACTERIAL INFECTIONS. THE AQUACULTURE INDUSTRY LACKS A MEDICATED PRODUCT DEVELOPED FOR LARVAL ANIMALS. MICROENCAPSULATION IS CURRENTLY BEING TESTED AS A DELIVERY SYSTEM OF LIVE FOOD REPLACEMENTS FOR AQUATIC LARVAL SPECIES. WE PROPOSE TO ENCAPSULATE ANTIBIOTICS AND VITAMIN SUPPLEMENTS WITHIN MICROCAPSULES SUBSEQUENTLY INCORPORATED INTO LIPID-ENRICHED MICROPARTICLES. MICROCAPSULES WILL BE PRODUCED BY A PROCESS THAT WILL PROTECT THE LOW MOLECULAR WEIGHT, WATER-SOLUBLE ANTIBIOTICS AND VITAMINS UNTIL INGESTION BY PENAEID SHRIMP LARVAE. IN-VITRO ANTIBIOTIC LEACHING RATES WILL BE CORRELATED WITH SURVIVAL OF "MEDICATED" LARVAE AGAINST VIBRIO SP. CHALLENGE TO DETERMINEFEASIBILITY FOR PHASE-II R&D. RESULTS OF IN-VITRO TESTS ANDWHOLE ANIMAL RESPONSES TO TEST MEDICATIONS, INCLUDING A CHALLENGE WITH LIVE BACTERIA, WILL DETERMINE COMMERCIALIZATION POTENTIAL.